Seven Victims Hospitalised in Victoria Over Suspected Counterfeit Retatrutide Batch

A cluster of seven acute liver toxicity cases has emerged in Victoria, each associated with the use of an unregulated peptide labeled as retatrutide. Liver transplant expert Marie Sinclair reported that patients fell seriously ill after a second dose and hypothesised that a contaminated counterfeit batch might be responsible, though laboratory results are not yet available. The Therapeutic Goods Administration’s chief medical advisor Robyn Langham described the incidents as a localized batch issue and emphasized that the product being sold is not the clinically tested retatrutide.

Eli Lilly, which holds the retatrutide patent and is conducting clinical trials, warned consumers that any online version is unverified and risky. The TGA disclosed the destruction of over 94,500 unapproved peptide items this year and recent joint seizures with Australian Border Force and New South Wales Police totalling millions of dollars. Health officials highlighted concerns about young people obtaining such products via social media, underscoring broader public-health risks from the illegal peptide market.